See more : Mondi plc (MNDI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Eloxx Pharmaceuticals, Inc. (ELOX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eloxx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LifeSafe Holdings plc (LIFS.L) Income Statement Analysis – Financial Results
- Godrej Agrovet Limited (GODREJAGRO.BO) Income Statement Analysis – Financial Results
- Stryker Corporation (0R2S.L) Income Statement Analysis – Financial Results
- IQE plc (IQE.L) Income Statement Analysis – Financial Results
- IMV Corporation (7760.T) Income Statement Analysis – Financial Results
Eloxx Pharmaceuticals, Inc. (ELOX)
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,871,400.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.73M | 45.57M | 14.59M | 26.35M | 20.49M | 16.40M | 733.66K | 2.18M | 4.57M | 3.34M | 2.09M | 2.57M | 3.72M | 2.64M | 2.35M | 1.76M | 1.21M | 1.57M | 1.42M | 1.15M | 793.90K | 370.19K | 479.47K | 476.46K | 173.46K | 0.00 | 0.00 |
| General & Administrative | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34M | 1.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.72K | 574.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 2.35M | 2.21M | 2.29M | 2.41M | 1.92M | 2.03M | 2.91M | 1.48M | 1.94M | 1.49M | 1.97M | 982.40K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -115.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.37K | -7.81K |
| Operating Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Cost & Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Interest Income | 274.00K | 8.00K | 337.00K | 1.07M | 601.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.48K | 0.00 | 0.00 | 43.08K | 100.45K | 69.30K | 0.00 | 54.03K | 0.00 | 0.00 | 24.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.95M | 1.26M | 1.41M | 1.62M | 7.00K | 43.00K | 265.20K | 533.00 | 2.77K | 77.44K | 119.09K | 134.55K | 88.12K | 610.67K | 1.01M | 434.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.00K | 960.00K | 571.00K | 559.00K | 216.00K | 39.00K | 44.08K | 93.39K | 177.07K | 349.66K | 293.63K | 258.02K | 143.27K | 126.57K | 111.75K | 96.85K | 166.17K | 40.11K | 43.72K | 30.42K | 38.70K | 24.36K | 24.16K | 18.71K | 4.00K | 0.00 | 0.00 |
| EBITDA | -33.37M | -66.02M | -33.46M | -50.56M | -46.15M | -20.39M | -4.59B | -8.85M | -17.88M | -8.80M | -4.65B | -4.83M | -6.33B | -4.72M | -4.17M | -3.50M | -3.15M | -3.38M | -3.28M | -4.01M | -2.23M | -2.09M | -1.95M | -2.43M | -1.15M | -10.37K | -7.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,827.52% | -9,982.48% | -6,572.38% | 0.00% | -2,491.85% | 0.00% | 2,290.26% | -1,343.62% | -620.45% | -1,051.61% | -5,068.89% | -2,853.45% | -25,703.22% | -23,608.61% | -1,120.21% | -200,724,000.00% | -242,873,500.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.42M | -66.02M | -33.46M | -50.56M | -47.57M | -20.39M | -4.59M | -11.19M | -18.08M | -9.15M | -4.65M | -5.41M | -7.92M | -4.85M | -4.28M | -3.60M | -3.32M | -3.42M | -3.32M | -4.04M | -2.27M | -2.11M | -1.97M | -2.45M | -1.16M | -10.37K | -7.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,926.64% | -24,102.31% | -9,147.80% | 0.00% | -2,705.76% | 0.00% | -3,461.80% | -1,558.07% | -788.11% | -1,107.00% | -5,129.06% | -2,657.39% | -24,223.34% | -22,686.06% | -1,057.12% | -197,107,000.00% | -244,744,800.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -709.00K | -1.12M | -319.00K | 502.00K | -824.00K | -2.24M | 2.25M | 12.95K | -77.44K | -1.47M | 345.40K | 649.73K | 4.85M | 4.28M | 3.60M | 3.32M | 3.42M | 1.13M | 959.02K | 130.95K | 150.55K | 60.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -36.07M | -66.73M | -34.58M | -50.87M | -47.06M | -21.21M | -6.84M | -8.95M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -12.77M | -4.76M | -4.27M | 0.00 | 0.00 | -3.03M | -3.76M | -2.14M | -1.96M | -1.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,930.57% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,123.46% | -1,731.89% | -934.55% | 0.00% | 0.00% | -2,426.36% | -22,560.92% | -21,376.54% | -981.84% | -191,073,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.26M | 1.41M | 1.62M | 122.00K | 43.00K | -1.04M | -680.00K | 2.77K | 77.44K | 119.09K | -24.26K | 1.07M | 8.54M | 1.44M | 1.00M | -69.30K | -104.46K | -342.82K | -310.35K | -202.27K | -174.81K | -94.08K | -2.53K | 13.14K | 10.37K | 7.81K |
| Net Income | -36.07M | -66.73M | -34.58M | -50.87M | -47.19M | -21.21M | -5.80M | -8.27M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -13.38M | -5.73M | -4.60M | -3.25M | -3.31M | -2.98M | -3.73M | -2.07M | -1.94M | -1.88M | -2.44M | -1.17M | -10.37K | -7.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,023.91% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,559.65% | -2,082.50% | -1,007.62% | -1,083.90% | -4,972.38% | -2,383.13% | -22,361.26% | -20,663.38% | -969.71% | -187,699,100.00% | -244,491,600.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| Weighted Avg Shares Out | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
| Weighted Avg Shares Out (Dil) | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and...
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed...
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an...
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations
Source: https://incomestatements.info
Category: Stock Reports